Versartis (VSAR) Narrows Q4 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Versartis (VSAR) Narrows Q4 Loss

Versartis Reports Fourth Quarter and Full Year 2014 Financial Results

February 12, 2015 4:52 PM EST

MENLO PARK, Calif., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq: VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced financial results for the fourth quarter and full year ended December 31, 2014.

"We continue to advance our clinical development strategy, most significantly by the recent initiation of the global Phase 3 VELOCITY trial of VRS-317 for semi-monthly dosing in pediatric growth hormone deficiency (GHD) patients," said Jeffrey L. Cleland, PhD, Chief Executive Officer. "Furthermore, we reported positive 12 month data from our ongoing Extension Study that... More